MedTrace Logo

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

NCT05088369 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2023-02-01

No results posted yet for this study

Summary

This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD \& MAD Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.

Conditions

Interventions

DRUG

HM201

HM201 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

DRUG

HM201

HM201 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

Sponsors & Collaborators

  • Himuka AM Pharma Corp.

    collaborator UNKNOWN

  • Syneos Health

    lead OTHER

Principal Investigators

  • Kristi McLendon, MD · Nucleus Network Pty Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2022-12-19
Completion
2022-12-19

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088369 on ClinicalTrials.gov